Repligen Corp (RGEN)

Price$122.31

Value ScoreD

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-36.41%

Price vs S&P 500 (4W)-0.92%

VGM Score45.91

Market Capitalization$6.90B

P/E Ratio (Annual)141.11x

All Metrics

P/CF (Annual)58.76x

Book Value / Share (Quarterly)$37.33

P/TBV (Annual)5.36x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.70%

Cash Flow / Share (Quarterly)$1.85

Price vs S&P 500 (YTD)-33.51%

Gross Margin (TTM)53.14%

Net Profit Margin (TTM)6.73%

EPS (TTM)$0.91

10-Day Avg Trading Volume0.92M

EPS Excl Extra (TTM)$0.91

Revenue Growth (5Y)15.05%

EPS (Annual)$0.86

ROI (Annual)1.85%

Gross Margin (Annual)52.65%

Net Profit Margin (5Y Avg)10.10%

Cash / Share (Quarterly)$13.91

P/E Basic Excl Extra (TTM)134.23x

Revenue Growth QoQ (YoY)14.83%

EPS Growth (5Y)-4.90%

P/E Normalized (Annual)141.11x

ROA (Last FY)1.66%

Revenue Growth TTM (YoY)18.23%

EBITD / Share (TTM)$2.31

ROE (5Y Avg)3.98%

Operating Margin (TTM)6.65%

Cash Flow / Share (Annual)$1.63

P/B Ratio3.28x

P/B Ratio (Quarterly)3.16x

Net Income / Employee (Annual)$24,400

EV / Revenue (TTM)8.99x

Net Interest Coverage (TTM)13.28x

ROA (TTM)1.76%

EPS Growth QoQ (YoY)42.68%

EV / EBITDA (TTM)52.56x

EPS Incl Extra (Annual)$0.86

Current Ratio (Annual)8.37x

Quick Ratio (Quarterly)7.42x

3-Month Avg Trading Volume1.02M

52-Week Price Return-3.46%

EV / Free Cash Flow (Annual)74.85x

P/E Incl Extra (TTM)134.23x

Revenue / Employee (TTM)$381,700

Tangible BV / Share (Quarterly)$30.80

P/S Ratio (Annual)9.35x

Asset Turnover (Annual)0.25x

52-Week High$175.77

Operating Margin (5Y Avg)12.08%

EPS Excl Extra (Annual)$0.86

CapEx CAGR (5Y)-0.44%

Tangible BV CAGR (5Y)6.73%

26-Week Price Return-28.48%

Quick Ratio (Annual)7.02x

13-Week Price Return-2.18%

Total Debt / Equity (Annual)0.26x

Current Ratio (Quarterly)9.20x

Enterprise Value$6.86B

Revenue / Share Growth (5Y)13.94%

Asset Turnover (TTM)0.26x

Book Value / Share Growth (5Y)6.03%

Revenue / Employee (Annual)$369,100

Inventory Turnover (Annual)2.23x

Pretax Margin (Annual)8.45%

Cash / Share (Annual)$13.63

3-Month Return Std Dev52.83%

Gross Margin (5Y Avg)53.29%

Net Income / Employee (TTM)$25,700

EBITDA CAGR (5Y)9.31%

EBITDA Interim CAGR (5Y)-13.31%

ROE (Last FY)2.32%

Net Interest Coverage (Annual)-3.82x

EPS Basic Excl Extra (Annual)$0.86

P/FCF (TTM)66.05x

Receivables Turnover (TTM)5.11x

EV / Free Cash Flow (TTM)65.70x

Total Debt / Equity (Quarterly)0.26x

EPS Incl Extra (TTM)$0.91

Receivables Turnover (Annual)5.04x

ROI (TTM)1.95%

P/S Ratio (TTM)9.04x

Pretax Margin (5Y Avg)12.66%

Revenue / Share (Annual)$13.05

Tangible BV / Share (Annual)$30.54

Forward P/E55.70x

Free OCF CAGR (5Y)20.36%

Price vs S&P 500 (52W)-27.83%

P/E Ratio (TTM)134.23x

Year-to-Date Return-25.36%

5-Day Price Return-0.64%

EPS Normalized (Annual)$0.86

ROA (5Y Avg)2.97%

Net Profit Margin (Annual)6.62%

Month-to-Date Return-1.32%

Cash Flow / Share (TTM)$3.18

EBITD / Share (Annual)$2.37

EPS Growth (3Y)-35.59%

Operating Margin (Annual)7.47%

LT Debt / Equity (Annual)0.26x

P/CF (TTM)52.78x

ROI (5Y Avg)3.42%

P/E Excl Extra (TTM)134.23x

LT Debt / Equity (Quarterly)0.26x

EPS Basic Excl Extra (TTM)$0.91

P/TBV (Quarterly)3.82x

P/B Ratio (Annual)4.38x

Inventory Turnover (TTM)2.15x

Pretax Margin (TTM)7.36%

Book Value / Share (Annual)$37.39

Price vs S&P 500 (13W)-10.43%

Net Margin Growth (5Y)-16.54%

Beta1.07x

P/FCF (Annual)75.25x

Revenue / Share (TTM)$13.47

ROE (TTM)2.46%

52-Week Low$100.99

vGradeD

gGradeB

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.48est. 0.39

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.07

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
RGENRepligen Corp	D	B	C	$122.31
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Repligen develops and sells bioprocessing equipment and supplies for manufacturing biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. The company serves biopharmaceutical companies and contract manufacturers globally with four core product categories: filtration and fluid management (55% of revenue), chromatography (21%), proteins (11%), and process analytics (13%). Revenue is geographically balanced across North America (44%), Europe (37%), and Asia Pacific (19%).